Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Target Raised at Guggenheim

Neurocrine Biosciences (NASDAQ:NBIX) had its target price raised by Guggenheim from $207.00 to $224.00 in a report released on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

Several other equities research analysts have also issued reports on the company. Stifel Nicolaus upped their price target on Neurocrine Biosciences from $188.00 to $215.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Morgan Stanley lifted their price objective on shares of Neurocrine Biosciences from $183.00 to $185.00 and gave the stock an “equal weight” rating in a report on Tuesday. Wells Fargo & Company boosted their target price on shares of Neurocrine Biosciences from $175.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. BMO Capital Markets dropped their target price on shares of Neurocrine Biosciences from $164.00 to $150.00 and set a “market perform” rating on the stock in a report on Monday, October 12th. Finally, Canaccord Genuity Group increased their target price on shares of Neurocrine Biosciences from $210.00 to $220.00 and gave the stock a “buy” rating in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $202.32.

Neurocrine Biosciences Stock Up 0.7%

Shares of NASDAQ NBIX opened at $166.05 on Wednesday. The stock’s 50 day moving average price is $146.98 and its two-hundred day moving average price is $147.77. Neurocrine Biosciences has a 52-week low of $122.14 and a 52-week high of $186.12. The stock has a market capitalization of $16.81 billion, a P/E ratio of 24.64, a PEG ratio of 0.73 and a beta of 0.36.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Monday, November 2nd. The company reported $3.29 EPS for the quarter, topping the consensus estimate of $1.91 by $1.38. Neurocrine Biosciences had a return on equity of 23.39% and a net margin of 18.98%. The company had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.04 billion. During the same quarter last year, the firm earned $2.04 EPS. The business’s revenue was up 41.3% on a year-over-year basis. On average, analysts anticipate that Neurocrine Biosciences will post 7.66 EPS for the current year.

Insider Buying and Selling

In related news, insider David Boyer sold 826 shares of the company’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $157.45, for a total value of $130,053.70. Following the completion of the sale, the insider owned 8,722 shares of the company’s stock, valued at $1,373,278.90. This represents a 8.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director George J. Morrow sold 7,200 shares of the stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $166.37, for a total transaction of $1,197,864.00. Following the completion of the transaction, the director owned 10,386 shares of the company’s stock, valued at $1,727,918.82. This represents a 40.94% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 18,137 shares of company stock valued at $2,829,332 over the last 90 days. 4.60% of the stock is currently owned by company insiders.

Institutional Trading of Neurocrine Biosciences

A number of institutional investors have recently made changes to their positions in the stock. Entrust Financial LLC increased its stake in shares of Neurocrine Biosciences by 62.9% during the third quarter. Entrust Financial LLC now owns 202 shares of the company’s stock valued at $29,000 after acquiring an additional 78 shares during the period. Raleigh Capital Management Inc. raised its holdings in Neurocrine Biosciences by 561.8% during the third quarter. Raleigh Capital Management Inc. now owns 225 shares of the company’s stock worth $32,000 after purchasing an additional 191 shares in the last quarter. Basecamp Wealth Advisors LLC lifted its position in Neurocrine Biosciences by 582.9% in the first quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock worth $31,000 after purchasing an additional 204 shares during the period. Cassaday & Co Wealth Management LLC acquired a new stake in Neurocrine Biosciences in the first quarter worth approximately $33,000. Finally, TrinityBridge Ltd bought a new position in Neurocrine Biosciences during the 2nd quarter valued at $45,000. 92.59% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Neurocrine reported Q3 revenue of $1.12 billion, up 41% year over year and above expectations, with EPS of $3.29 also beating estimates. The company raised its 2026 INGREZZA sales outlook to $2.9–$2.925 billion, reflecting product demand and supporting the growth outlook. Q3 results and updated sales outlook
• Positive Sentiment: Guggenheim raised its price target to $224 from $207 and maintained a Buy rating. Canaccord, Piper Sandler and RBC also lifted their targets after the results, adding to a broadly favorable analyst response.
• Neutral Sentiment: The company has started a Phase 2 Alzheimer’s study, offering a potential longer-term pipeline opportunity, but the supplied report provides few details on the study or its prospects. Alzheimer’s study update
• Negative Sentiment: Director George J. Morrow reported selling shares in multiple transactions, including sales on November 2 and 3. The filings indicate the trades were made under a pre-arranged Rule 10b5-1 plan, which may lessen the significance, but insider selling can still concern investors.
• Negative Sentiment: A report flagged potential integration challenges and legacy liabilities related to Neurocrine’s Soleno acquisition, which could affect how much value the company ultimately captures from the deal. Soleno acquisition risks

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.